Literature DB >> 23383607

Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.

E Berntorp1, B Fuchs, M Makris, R Montgomery, V Flood, J S O'Donnell, A B Federici, D Lillicrap, P James, U Budde, M Morfini, P Petrini, S Austin, C Kannicht, V Jiménez-Yuste, C Lee.   

Abstract

The first meeting of international specialists in the field of von Willebrand disease (VWD) was held in the Åland islands in 1998 where Erik von Willebrand had first observed a bleeding disorder in some members of a family from Föglö and a summary of the meeting was published in 1999. The second meeting was held in 2010 and a report of the meeting was published in 2012. Topics covered included progress in understanding of VWD over the last 50 years; multimers; classification of VWD; pharmacokinetics and laboratory assays; genetics; treating the paediatric patient; prophylaxis; geriatrics; gene therapy and treatment guidelines. This third meeting held over 3 days covered the structure and function of von Willebrand factor (VWF); type 1 VWD, the most common form of the disease; a lifespan of pharmacokinetics in VWD; detecting inhibitors in VWD patients; and special challenges in understanding and treating the female VWD patient.
© 2013 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23383607      PMCID: PMC4164969          DOI: 10.1111/hae.12078

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  90 in total

Review 1.  Clearance mechanisms of von Willebrand factor and factor VIII.

Authors:  P J Lenting; C J M VAN Schooten; C V Denis
Journal:  J Thromb Haemost       Date:  2007-04-07       Impact factor: 5.824

2.  Review of a multidisciplinary clinic for women with inherited bleeding disorders.

Authors:  C A Lee; C Chi; N Shiltagh; D Pollard; A Griffioen; N Dunn; R A Kadir
Journal:  Haemophilia       Date:  2008-08-08       Impact factor: 4.287

3.  Platelet factor VIII-related antigen: studies in vivo after transfusion in patients with von Willebrand disease.

Authors:  Y Sultan; C Jeanneau; J Lamaziere; P Maisonneuve; J P Caen
Journal:  Blood       Date:  1978-04       Impact factor: 22.113

4.  Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.

Authors:  S R Deitcher; J Tuller; J A Johnson
Journal:  Haemophilia       Date:  1999-03       Impact factor: 4.287

5.  A common 253-kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3.

Authors:  R Schneppenheim; G Castaman; A B Federici; W Kreuz; R Marschalek; J Oldenburg; F Oyen; U Budde
Journal:  J Thromb Haemost       Date:  2007-02-26       Impact factor: 5.824

6.  Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase.

Authors:  K L Mohlke; A A Purkayastha; R J Westrick; P L Smith; B Petryniak; J B Lowe; D Ginsburg
Journal:  Cell       Date:  1999-01-08       Impact factor: 41.582

7.  The role of platelet von Willebrand factor in platelet adhesion and thrombus formation: a study of 34 patients with various subtypes of type I von Willebrand disease.

Authors:  E Fressinaud; A B Federici; G Castaman; C Rothschild; F Rodeghiero; H R Baumgartner; P M Mannucci; D Meyer
Journal:  Br J Haematol       Date:  1994-02       Impact factor: 6.998

8.  Acquired von Willebrand syndrome in aortic stenosis.

Authors:  André Vincentelli; Sophie Susen; Thierry Le Tourneau; Isabelle Six; Olivier Fabre; Francis Juthier; Anne Bauters; Christophe Decoene; Jenny Goudemand; Alain Prat; Brigitte Jude
Journal:  N Engl J Med       Date:  2003-07-24       Impact factor: 91.245

9.  Von Willebrand disease: an update in the Aland islands.

Authors:  E Berntorp; J Ingerslev; S Schulman
Journal:  Haemophilia       Date:  1999-05       Impact factor: 4.287

10.  Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium.

Authors:  Nicholas L Smith; Ming-Huei Chen; Abbas Dehghan; David P Strachan; Saonli Basu; Nicole Soranzo; Caroline Hayward; Igor Rudan; Maria Sabater-Lleal; Joshua C Bis; Moniek P M de Maat; Ann Rumley; Xiaoxiao Kong; Qiong Yang; Frances M K Williams; Veronique Vitart; Harry Campbell; Anders Mälarstig; Kerri L Wiggins; Cornelia M Van Duijn; Wendy L McArdle; James S Pankow; Andrew D Johnson; Angela Silveira; Barbara McKnight; Andre G Uitterlinden; Nena Aleksic; James B Meigs; Annette Peters; Wolfgang Koenig; Mary Cushman; Sekar Kathiresan; Jerome I Rotter; Edwin G Bovill; Albert Hofman; Eric Boerwinkle; Geoffrey H Tofler; John F Peden; Bruce M Psaty; Frank Leebeek; Aaron R Folsom; Martin G Larson; Timothy D Spector; Alan F Wright; James F Wilson; Anders Hamsten; Thomas Lumley; Jacqueline C M Witteman; Weihong Tang; Christopher J O'Donnell
Journal:  Circulation       Date:  2010-03-15       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.